Endocrine therapy is an essential part of a comprehensive treatment for patients with estrogen receptor-positive (ER+) breast cancer (BC), including drugs that act as antagonists of the estrogen receptors, aromatase inhibitors, and drugs that promote the downregulation of the estrogen receptor [1, 2]. The gene discussed is CYP19A1; the disease is breast cancer.